Objective measurement of muscle co-contraction pre-and post-Botulinum Toxin-A injection in adults with focal spasticity

A/Prof Ian Baguley0 个研究点目标入组 90 人开始时间: 2023年11月3日最近更新: 2023年11月13日

适应症

试验速览

暂无简介。

•Clinical Group:
•Ability to understand verbal instructions in English
•Motor overactivity resulting from an UMN syndrome of greater than 3 months duration
•Predominately unilateral disability.
•Presence of active grip strength in the most affected upper limb (a minimum of 0.75kg of force)
•* People who are receiving Botulinum Toxin-A injections as part of their spasticity management.
•Control group
•Age 18+ years
•Ability to understand verbal instructions in English
•Available for two assessments

•Other causes of upper limb weakness including non-neurological pain, rheumatological conditions, lower motor neuron lesions, etc.
•Inadequate ability to understand and follow instructions, such as language barriers or inadequate voluntary motor control.
•People with spasticity who are not being offered OnabotulinumtoxinA injections as a clinical treatment.
•* People with a known contraindication to OnabotulinumtoxinA e.g., Eaton-Lambert syndrome, pregnancy, hypersensitivity etc.
•Control group
•Self-reported neurological impairment
•Self-reported acute or chronic arm injury or impairment

发起方

A/Prof Ian Baguley